Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 73.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 516,469 shares of the biopharmaceutical company's stock after selling 1,452,700 shares during the quarter. Handelsbanken Fonder AB owned about 0.41% of Halozyme Therapeutics worth $24,692,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of HALO. CWM LLC grew its stake in shares of Halozyme Therapeutics by 77.5% during the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company's stock valued at $88,000 after buying an additional 668 shares during the last quarter. Creative Planning grew its stake in shares of Halozyme Therapeutics by 25.6% during the third quarter. Creative Planning now owns 46,834 shares of the biopharmaceutical company's stock valued at $2,681,000 after buying an additional 9,543 shares during the last quarter. Raymond James & Associates grew its stake in shares of Halozyme Therapeutics by 87.1% during the third quarter. Raymond James & Associates now owns 273,591 shares of the biopharmaceutical company's stock valued at $15,660,000 after buying an additional 127,330 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of Halozyme Therapeutics by 6.2% during the third quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company's stock valued at $1,383,000 after buying an additional 1,410 shares during the last quarter. Finally, International Assets Investment Management LLC grew its stake in shares of Halozyme Therapeutics by 5,623.9% during the third quarter. International Assets Investment Management LLC now owns 36,576 shares of the biopharmaceutical company's stock valued at $20,940,000 after buying an additional 35,937 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HALO. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Benchmark reaffirmed a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. HC Wainwright boosted their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $62.78.

Halozyme Therapeutics Stock Up 0.5 %

Halozyme Therapeutics stock traded up $0.31 during mid-day trading on Friday, reaching $57.75. 1,299,523 shares of the company were exchanged, compared to its average volume of 1,313,186. The business has a fifty day moving average of $53.46 and a 200 day moving average of $54.62. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a market cap of $7.11 billion, a P/E ratio of 16.84, a PEG ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.40% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.